Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC – Get Free Report) saw a large decrease in short interest in July. As of July 15th, there was short interest totaling 58,489 shares, a decrease of 38.3% from the June 30th total of 94,847 shares. Based on an average daily trading volume, of 825,988 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are sold short.
Oncotelic Therapeutics Price Performance
OTLC traded down $0.00 during midday trading on Thursday, reaching $0.04. 52,136 shares of the company’s stock were exchanged, compared to its average volume of 291,191. The company has a quick ratio of 0.11, a current ratio of 0.11 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $17.56 million, a price-to-earnings ratio of 0.07 and a beta of -0.27. Oncotelic Therapeutics has a one year low of $0.01 and a one year high of $0.11. The business has a 50-day simple moving average of $0.05 and a two-hundred day simple moving average of $0.05.
About Oncotelic Therapeutics
Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.
Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.
Featured Stories
- Five stocks we like better than Oncotelic Therapeutics
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Oncotelic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncotelic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
